PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: HER-2 Positive Breast Cancer
Interventions: OTHER: Efficacy of the Pertuzumab-Trastuzumab combination
Sponsor: Hospices Civils de Lyon